Choosing initial antiretroviral therapy: Current recommendations for initial therapy and newer or investigational agents

Topics in Antiviral Medicine

Volumn 23, Issue 4, 2015, Pages 128-131

  Gulick, Roy M ^a   Harriman, Roland ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Antiretroviral drugs; BMS 663068; BMS 955176; Cabotegravir; CD4 attachment inhibitor; Doravirine; HIV; HIV maturation inhibitor; Initial therapy; TAF; Tenofovir

Indexed keywords

ABACAVIR; ABACAVIR PLUS DOLUTEGRAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE; ANTIRETROVIRUS AGENT; ATAZANAVIR; BEVIRIMAT; BMS 955176; CABOTEGRAVIR; COBICISTAT; CYTOCHROME P450; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; DOLUTEGRAVIR; DORAVIRINE; EFAVIRENZ; EMTRICITABINE; FOSTEMSAVIR; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; LAMIVUDINE; LOPINAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RIFAMPICIN; RILPIVIRINE; RITONAVIR; RNA; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR ALAFENAMIDE; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DRUG SENSITIVITY; DRUG TOLERABILITY; GLOMERULUS FILTRATION RATE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IC50; MAINTENANCE THERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); SYSTEMATIC REVIEW (TOPIC); VIRUS LOAD; WORLD HEALTH ORGANIZATION; EUROPE; HIV INFECTIONS; PROCEDURES; TREATMENT OUTCOME; UNITED STATES;

ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; EUROPE; HIV INFECTIONS; HUMANS; TREATMENT OUTCOME; UNITED STATES;

EID: 84949493908     PISSN: 21615861     EISSN: 21615853     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Lee FJ, Amin J, Carr A. Efficacy of initial antiretroviral therapy for HIV-1 infection in adults: a systematic review and meta-analysis of 114 studies with up to 144 weeks' follow-up. PLoS One. 2014; 9(5):e97482.
2. Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369(19): 1807-1818.
3. Clotet B, Feinberg J, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomized open-label phase 3b study. Lancet. 2014;383(9936):2222-2231.
4. Lennox JL, Landovitz RJ, Ribaudo HJ, et al. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med. 2014;161(7):461-471.
5. Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015;385(9987):2606-2615.
6. Gill VS, Lima VD, Zhang W, et al. Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. Clin Infect Dis. 2010;50(1):98-105.
7. Günthard HF, Aberg JA, Eron JJ, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society–USA panel. JAMA. 2014;312(4):410-425.
8. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed on November 30, 2015.
9. European AIDS Clinical Society. European guidelines for clinical management and treatment of HIV-infected adults in Europe. http://www.eacsociety.org/files/guidelines-7.1-english.pdf. Accessed on November 6, 2015.
10. Churchill D, Waters L, Ahmed N, et al. BHIVA guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015. http://www.bhiva.org/documents/Guidelines/Treatment/2015/2015-treatment-guidelines.pdf. Accessed on November 30, 2015.
11. World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. http://apps.who.int/iris/bitstream/10665/186275/1/9789241509565_eng.pdf?ua=1. Accessed on November 30, 2015.
12. Raffi F, Rachlis A, Stellbrink HJ, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381(9868):735-743.
13. Lawson EB, Martin H, McCallister S et al. Drug interactions between tenofovir alafenamide and HIV antiretroviral agents. Interscience Conference of Antimicrobial Agents and Chemotherapy. September 5-9, 2014; Washington, DC.
14. Lai MT, Feng M, Falgueyret JP, et al. In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother. 2014;58(3):1652-1663.
15. Yee KL, Khalilieh SG, Liu R, et al. The effect of single and multiple dose rifampin on the pharmacokinetics of doravirine [CROI abstract 521]. In Special Issue: Abstracts From the 2015 Conference on Retroviruses and Opportunistic Infections. Top Antivir Med. 2015; 23(e-1):217.
16. Anderson MS, Gilmartin J, Cilissen C, et al. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects. Antivir Ther. 2014;20(4):397-405.
17. Schurmann D, Sobotha C, Gilmartin J, et al. A randomized, doubleblind, placebo-controlled, short-term monotherapy study of doravirine in treatment-naive HIV-infected patients. AIDS. 2015; [Epub ahead of print].
18. Morales-Ramirez JO, Gatell JM, Hagins DP, et al. Safety and antiviral effect of MK-1439, a novel NNRTI (+FTC/TDF) in ART-naive HIVinfected patients [CROI Abstract 92LB]. In Special Issue: Abstracts From the 2014 Conference on Retroviruses and Opportunistic Infections. Top Antivir Med. 2014;22(e-1):46-47.
19. Gatell JM, Morales-Ramirez JO, Hagins DP, et al. Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naive HIV-positive patients. J Int AIDS Soc. 2014;17(4 Suppl 3):19532.
20. Spreen W, Ford SL, Chen S, et al. GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects. JAIDS 2014;67(5):481-486.
21. Margolis DA, Brinson CC, Smith GH, et al. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. Lancet Infect Dis. 2015;15(10):1145-1155.
22. Nettles RE, Schurmann D, Zhu L, et al. Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects. J Infect Dis. 2012;206(7):1002-1011.
23. Thompson M, Lalezari J, Kaplan R, et al. Attachment inhibitor prodrug BMS-663068 in ARV-experienced subjects: week 48 analysis [CROI abstract 545]. In Special Issue: Abstracts From the 2015 Conference on Retroviruses and Opportunistic Infections. Top Antivir Med. 2015;23(e-1):227-228.
24. Landry IS, Zhu L, Abutarif M, et al. HIV-1 attachment inhibitor prodrug BMS-663068: model-based dose selection [CROI abstract 509]. In Special Issue: Abstracts From the 2015 Conference on Retroviruses and Opportunistic Infections. Top Antivir Med. 2015;23 (e-1):211.
25. Hwang C, Schurmann D, Sobotha C, et al. Antiviral activity/safety of a second-generation HIV-1 maturation inhibitor [CROI abstract 114LB]. In Special Issue: Abstracts From the 2015 Conference on Retroviruses and Opportunistic Infections. Top Antivir Med. 2015; 23(e-1):48.